Literature DB >> 11463350

Effect of chemical modification of recombinant human acetylcholinesterase by polyethylene glycol on its circulatory longevity.

O Cohen1, C Kronman, T Chitlaru, A Ordentlich, B Velan, A Shafferman.   

Abstract

Post-translational modifications were recently shown to be responsible for the short circulatory mean residence time (MRT) of recombinant human acetylcholinesterase (rHuAChE) [Kronman, Velan, Marcus, Ordentlich, Reuveny and Shafferman (1995) Biochem. J. 311, 959--967; Chitlaru, Kronman, Zeevi, Kam, Harel, Ordentlich, Velan and Shafferman (1998) Biochem. J. 336, 647--658; Chitlaru, Kronman, Velan and Shafferman (2001) Biochem. J. 354, 613--625], which is one of the major obstacles to the fulfilment of its therapeutic potential as a bioscavenger. In the present study we demonstrate that the MRT of rHuAChE can be significantly increased by the controlled attachment of polyethylene glycol (PEG) side chains to lysine residues. Attachment of as many as four PEG molecules to monomeric rHuAChE had minimal effects, if any, on either the catalytic activity (K(m)=0.09 mM and k(cat)=3.9 x 10(5) min(-1)) or the reactivity of the modified enzyme towards active-centre inhibitors, such as edrophonium and di-isopropyl fluorophosphate, or to peripheral-site ligands, such as propidium, BW284C51 and even the bulky snake-venom toxin fasciculin-II. The increase in MRT of the PEG-modified monomeric enzyme is linearly dependent, in the tested range, on the number of attached PEG molecules, as well as on their size. It appears that even low level PEG-conjugation can overcome the deleterious effect of under-sialylation on the pharmacokinetic performance of rHuAChE. At the highest tested ratio of attached PEG-20000/rHuAChE (4:1), an MRT of over 2100 min was attained, a value unmatched by any other known form of recombinant or native serum-derived AChE reported to date.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11463350      PMCID: PMC1222009          DOI: 10.1042/0264-6021:3570795

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Therapeutic antibody fragments with prolonged in vivo half-lives.

Authors:  A P Chapman; P Antoniw; M Spitali; S West; S Stephens; D J King
Journal:  Nat Biotechnol       Date:  1999-08       Impact factor: 54.908

Review 2.  Stabilization of substances in circulation.

Authors:  C Monfardini; F M Veronese
Journal:  Bioconjug Chem       Date:  1998 Jul-Aug       Impact factor: 4.774

Review 3.  Applications of site-specific chemical modification in the manufacture of biopharmaceuticals: I. An overview.

Authors:  R L Lundblad; R A Bradshaw
Journal:  Biotechnol Appl Biochem       Date:  1997-12       Impact factor: 2.431

4.  Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.

Authors:  Y Kamisaki; H Wada; T Yagura; A Matsushima; Y Inada
Journal:  J Pharmacol Exp Ther       Date:  1981-02       Impact factor: 4.030

5.  Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

Authors:  M J Knauf; D P Bell; P Hirtzer; Z P Luo; J D Young; N V Katre
Journal:  J Biol Chem       Date:  1988-10-15       Impact factor: 5.157

6.  Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins. Demonstration of concerted contributions of glycan sialylation and subunit assembly to the pharmacokinetic behavior of bovine acetylcholinesterase.

Authors:  C Kronman; T Chitlaru; E Elhanany; B Velan; A Shafferman
Journal:  J Biol Chem       Date:  2000-09-22       Impact factor: 5.157

Review 7.  PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimisation of coupling techniques.

Authors:  G E Francis; D Fisher; C Delgado; F Malik; A Gardiner; D Neale
Journal:  Int J Hematol       Date:  1998-07       Impact factor: 2.490

8.  Evaluation of anchorage-dependent cell propagation systems for production of human acetylcholinesterase by recombinant 293 cells.

Authors:  A Lazar; S Reuveny; C Kronman; B Velan; A Shafferman
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

9.  Mutagenesis of human acetylcholinesterase. Identification of residues involved in catalytic activity and in polypeptide folding.

Authors:  A Shafferman; C Kronman; Y Flashner; M Leitner; H Grosfeld; A Ordentlich; Y Gozes; S Cohen; N Ariel; D Barak
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

10.  Design and expression of organophosphorus acid anhydride hydrolase activity in human butyrylcholinesterase.

Authors:  C B Millard; O Lockridge; C A Broomfield
Journal:  Biochemistry       Date:  1995-12-12       Impact factor: 3.162

View more
  9 in total

1.  Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agents.

Authors:  Brian C Geyer; Latha Kannan; Pierre-Emmanuel Garnaud; Clarence A Broomfield; C Linn Cadieux; Irene Cherni; Sean M Hodgins; Shane A Kasten; Karli Kelley; Jacquelyn Kilbourne; Zeke P Oliver; Tamara C Otto; Ian Puffenberger; Tony E Reeves; Neil Robbins; Ryan R Woods; Hermona Soreq; David E Lenz; Douglas M Cerasoli; Tsafrir S Mor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey.

Authors:  Colin J Jackson; Colin Scott; Angela Carville; Keith Mansfield; David L Ollis; Steven B Bird
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

Review 3.  Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs.

Authors:  Yvonne Rosenberg; Ashima Saxena
Journal:  Neuropharmacology       Date:  2020-05-19       Impact factor: 5.250

4.  Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples.

Authors:  Tatsuya Kikuchi; Toshimitsu Okamura; Takuya Arai; Takayuki Obata; Kiyoshi Fukushi; Toshiaki Irie; Tetsuya Shiraishi
Journal:  Br J Pharmacol       Date:  2010-04       Impact factor: 8.739

5.  Overloading and removal of N-glycosylation targets on human acetylcholinesterase: effects on glycan composition and circulatory residence time.

Authors:  Theodor Chitlaru; Chanoch Kronman; Baruch Velan; Avigdor Shafferman
Journal:  Biochem J       Date:  2002-05-01       Impact factor: 3.857

6.  Amino acid domains control the circulatory residence time of primate acetylcholinesterases in rhesus macaques (Macaca mulatta).

Authors:  Ofer Cohen; Chanoch Kronman; Baruch Velan; Avigdor Shafferman
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

Review 7.  Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavenger.

Authors:  Yvonne J Rosenberg; James B Fink
Journal:  Ann N Y Acad Sci       Date:  2016-07-02       Impact factor: 5.691

8.  Pulmonary delivery of an aerosolized recombinant human butyrylcholinesterase pretreatment protects against aerosolized paraoxon in macaques.

Authors:  Yvonne J Rosenberg; Beth Laube; Lingjun Mao; Xiaoming Jiang; Segundo Hernandez-Abanto; Keunmyoung D Lee; Robert Adams
Journal:  Chem Biol Interact       Date:  2012-11-21       Impact factor: 5.192

Review 9.  Anticancer Activity of Toxins from Bee and Snake Venom-An Overview on Ovarian Cancer.

Authors:  Marius Alexandru Moga; Oana Gabriela Dimienescu; Cristian Andrei Arvătescu; Petru Ifteni; Liana Pleş
Journal:  Molecules       Date:  2018-03-19       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.